RXRX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Recursion Reports Q3 2026 Financial Results, Positive Clinical Data, and Sanofi Candidate Option

Nov 2, 2026

8-K

Recursion Announces Sanofi Options First Immunology Development Candidate from Collaboration

Oct 15, 2026

8-K

Recursion Pharmaceuticals and Tempus AI Amend Partnership and Enter into RNA Foundation Model License Agreement

Sep 21, 2026

8-K

Recursion Reports Q2 2026 Financial Results and Advances Neuroscience Collaboration with Genentech

Aug 5, 2026

8-K

Recursion Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Recursion Reports First Quarter 2026 Financial Results and Pipeline Progress

May 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Oct 15, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $200,000,000 | Bank: Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Evercore ISI, Needham & Company

Oct 15, 2026

424B5

February 2026 ATM | Offering amount: $300,000,000 | Bank: TD Cowen

Feb 25, 2026

424B7

SHARE RESALE REGISTRATION | Shares amount: 7,088,742

Nov 26, 2025

424B7

SHARE RESALE REGISTRATION | Shares amount: 2,397,023 | Share price: $5.21 |

Aug 29, 2025

424B7

SHARE RESALE REGISTRATION | Shares amount: 1,457,952 | Share price: $5.14

Jul 8, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 5, 2025

S-3ASR

SHARE RESALE REGISTRATION

Feb 12, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 20, 2024

S-8

Registration

May 9, 2024

S-8

Registration

May 30, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Nov 6, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 30, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Hassan Fred (Reporting)

Nov 4, 2026

Borgeson Blake (Reporting)

Nov 4, 2026

Hassan Fred (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

Borgeson Blake (Reporting)

Oct 7, 2026

HERSHBERG ROBERT (Reporting)

Oct 7, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jun 13, 2024

CORRESP

Form CORRESP - Correspondence

Jun 13, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 30, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 16, 2021

CORRESP

Form CORRESP - Correspondence

Apr 13, 2021

CORRESP

Form CORRESP - Correspondence

Apr 13, 2021

Recursion Pharmaceuticals, Inc. RXRX · SEC Filings